Dr Jenkins is the principal in his consulting firm William Jenkins Pharma Consulting and has been a consultant and advisor to a wide range of pharmaceutical and biotechnology companies, and also investment and venture capital firms in the health care sector, since 1999. Between 1996 and 1999 he was head of worldwide clinical development and regulatory affairs for Novartis Pharma AG, having previously held a similar position since 1992 with Ciba Geigy AG before its merger into Novartis. Prior to that, he was Head of Worldwide Clinical Research at Glaxo from 1988 to 1992, and before that served as a principal medical officer at the Medicines Division of the UK Department of Health.
Dr Jenkins is currently a director of a number of companies in the life sciences area, including BTG plc, Eurand Pharmaceutical Holdings B.V., Monogram Biosciences, Inc. and Vaximm AG.
Dr Peter Fellner, Chairman of Consort Medical said
William has exceptional experience across the life sciences field, including the successful development of several asthma treatments whilst at Novartis and Glaxo. He will be a very valuable addition to the Board.
George joined Consort Medical as a Non-executive Director in 2006. He has an outstanding record in the medical technology sector, and has made an important and sustained contribution to the Board, across many areas.
